July 31, 2025
Physicians who see patients with syphilis should note that there is a voluntary recall of specific lots of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension) by King Pharmaceuticals LLC., a subsidiary of Pfizer.
The recalled lots can be found at Pfizer: Bicillin Recall Letter. The Centers for Disease Control and Prevention (CDC) is not aware of any adverse events associated with this issue, and there is no indication at this time of reduced efficacy or need for retreatment.
Considering this recall and high levels of syphilis diagnoses in the United States (as detailed in the National Overview of STIs in 2023), CDC anticipates a limited supply of Bicillin L-A moving forward. Penicillin is the only recommended treatment for pregnant patients and babies with congenital syphilis. Given this information, the CDC recommends prioritizing Bicillin L-A for treating patients who are pregnant and for infants with congenital syphilis.
More information and full recommendations can be found on a resource created by the Minnestoa Department of Health - Bicillin L-A® Recall and Anticipated Shortage.
July 31, 2025
The MMA has signed on to an AMA letter opposing HR 3164, the “Ensuring Community Access to Pharmacist Services (ECAPS) Act,” in particular because it would allow “pharmacists to perform services that would normally only be authorized and covered if they were furnished by a physician.”
July 31, 2025
Nearly 140,000 Minnesotans will lose their healthcare coverage as a result of President Trump’s budget reconciliation bill, according to a preliminary analysis by the Minnesota Department of Human Services (DHS).
July 31, 2025
MMA members are encouraged to cast their vote for MMA’s future leaders as part of the annual MMA leadership election taking place August 1-31.